A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

  • Park, John (Primary Chief Investigator)
  • Sabanathan, Dhanusha (Associate Investigator)
  • Gurney, Howard (Associate Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Rai, Meenal (Clinical Trial Unit Staff)

Project: Research

Project Details

AcronymXL184-021
StatusActive
Effective start/end date28/08/2030/04/25